What is HC Wainwright’s Estimate for CRDL FY2026 Earnings?

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Research analysts at HC Wainwright lifted their FY2026 EPS estimates for Cardiol Therapeutics in a research note issued on Tuesday, May 12th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings of ($0.25) per share for the year, up from their previous forecast of ($0.27). HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Cardiol Therapeutics’ FY2027 earnings at ($0.31) EPS.

Cardiol Therapeutics (NASDAQ:CRDL) last released its earnings results on Monday, May 11th. The company reported ($0.07) earnings per share for the quarter, hitting the consensus estimate of ($0.07).

Other analysts have also issued reports about the company. raised Cardiol Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 3rd. Wall Street Zen raised Cardiol Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, April 5th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $8.00 target price on shares of Cardiol Therapeutics in a report on Monday, April 6th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $8.50.

Cardiol Therapeutics Stock Performance

Shares of CRDL opened at $1.36 on Thursday. Cardiol Therapeutics has a 52-week low of $0.88 and a 52-week high of $1.71. The firm has a market cap of $152.08 million, a price-to-earnings ratio of -4.86 and a beta of 0.77. The business’s fifty day moving average is $1.25 and its 200-day moving average is $1.10.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Tejara Capital Ltd boosted its holdings in shares of Cardiol Therapeutics by 95.1% during the 4th quarter. Tejara Capital Ltd now owns 5,130,122 shares of the company’s stock valued at $4,893,000 after acquiring an additional 2,500,000 shares in the last quarter. Bank of America Corp DE increased its holdings in Cardiol Therapeutics by 1,983.0% in the 3rd quarter. Bank of America Corp DE now owns 551,053 shares of the company’s stock worth $590,000 after purchasing an additional 524,598 shares in the last quarter. Integrity Alliance LLC. bought a new position in Cardiol Therapeutics in the fourth quarter valued at about $416,000. Citadel Advisors LLC raised its position in Cardiol Therapeutics by 1,132.6% in the third quarter. Citadel Advisors LLC now owns 463,462 shares of the company’s stock valued at $496,000 after purchasing an additional 425,862 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new stake in shares of Cardiol Therapeutics during the third quarter valued at about $249,000. 12.49% of the stock is currently owned by institutional investors.

About Cardiol Therapeutics

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.